# EDGAR Filing Document

**Accession Number:** 0001662579
**File Stem:** 0001628280-25-055804
**Filing Date:** 2025-12
**Character Count:** 2729
**Document Hash:** e2eb7f9bf00075a733436b8e7b71e05f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-25-055804.hdr.sgml**: 20260408

**ACCESSION NUMBER**: 0001628280-25-055804

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251208

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** C4 Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001662579
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 475617627
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 490 ARSENAL WAY
- **STREET 2:** SUITE 120
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472
- **BUSINESS PHONE:** (617) 231-0700

**MAIL ADDRESS:**
- **STREET 1:** 490 ARSENAL WAY
- **STREET 2:** SUITE 120
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472

December 8, 2025

**<u>VIA EDGAR</u>**

Office of Life Sciences

Division of Corporation Finance

U.S. Securities and Exchange Commission

100 F Street, NE

Washington, DC 20549

Attention: Mr. Tyler Howes

---

| | | |
|:---|:---|:---|
| **Re:** | **C4 Therapeutics, Inc.** | **C4 Therapeutics, Inc.** |
| | **Acceleration Request for Registration Statement on Form S-3** | **Acceleration Request for Registration Statement on Form S-3** |
| | **File No. 333-291696** | **File No. 333-291696** |
| | **Acceleration Request** | **Acceleration Request** |
| | **Requested Date:** | **December 10, 2025** |
| | **Requested Time:** | **4:05 p.m., Eastern Time** |

---

Dear Mr. Howes:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "**Act**"), C4 Therapeutics, Inc. (the "**Company**") hereby requests that the effective date of the above-referenced registration statement (the "**Registration Statement**") be accelerated to December 10, 2025, at 4:05 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Edwin O'Connor at (212) 813 8853.

If you have any questions regarding this request, please contact Edwin O'Connor of Goodwin Procter LLP at (212) 813 8853.

Sincerely,

C4 THERAPEUTICS, INC.

<u>/s/ Andrew J. Hirsch</u> <u>.</u> 

Andrew J. Hirsch.

President and Chief Executive Officer

 <br> cc: Jolie M. Siegel, *C4 Therapeutics, Inc.*Edwin O'Connor, Esq., *Goodwin Procter LLP*

<br>